Tolerogenic therapies in transplantation

Frontiers in Immunology

Volumn 3, Issue JUL, 2012, Pages

  Page, Eugenia K ^a   Dar, Wasim A ^a   Knechtle, Stuart J ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

B cell therapeutics; Cellular therapies; Costimulation blockade; Mixed chimerism; Regulatory T cells; T cell depletion; Tolerance; Transplantation

Indexed keywords

EID: 84874209354     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00198     Document Type: Article

References (184)

1. Adams, A. B.,Shirasugi, N., Durham, M. M., Strobert, E., Anderson, D., Rees, P., Cowan, S., Xu, H., Blinder, Y., Cheung, M., Hollenbaugh, D., Kenyon, N. S., Pearson, T. C., and Larsen, C. P. (2002). Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51, 265-270.
2. Adams, A. B., Shirasugi, N., Jones, T. R., Durham, M. M., Strobert, E. A., Cowan, S., Rees, P., Hendrix, R., Price, K., Kenyon, N. S., Hagerty, D., Townsend, R., Hollenbaugh, D., Pearson, T. C., and Larsen, C. P. (2005). Development of a chimeric anti-CD40monoclonalantibodythat synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 174, 542-550.
3. Aggarwal, S., and Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cellresponses. Blood 105,1815-1822.
4. Aksu, A. E., Horibe, E., Sacks, J., Ikeguchi, R., Breitinger, J., Scozio, M., Unadkat, J., and Feili-Hariri, M. (2008). Co-infusion of donor bone marrowwithhostmesenchymalstem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin. Immunol. 127, 348-358.
5. Allison, M. (2009). Genzyme backs Osiris, despite Prochymal flop. Nat. Biotechnol. 27, 966-967.
6. Alwayn, I. P., Xu, Y., Basker, M., Wu, C., Buhler, L., Lambrigts, D., Treter, S., Harper, D., Kitamura, H., Vitetta, E. S., Abraham, S., Awwad, M., White-Scharf, M. E., Sachs, D. H., Thall, A., and Cooper, D. K. (2001). Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20and CD22positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation 8, 157-171.
7. Ankrum, J., and Karp, J. M. (2010). Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol. Med. 16,203-209.
8. Aoyagi, T., Yamashita, K., Suzuki, T., Uno,M.,Goto,R.,Taniguchi,M.,Shimamura,T.,Takahashi,N.,Miura,T., Okimura, K., Itoh, T., Shimizu, A., Furukawa,H.,and Todo,S. (2009). A human anti-CD40 monoclonal anti- body, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am. J. Transplant. 9,1732-1741.
9. Ashton-Chess, J., Giral, M., Brouard, S., and Soulillou, J. P. (2007). Spontaneous operational tolerance after immunosuppressivedrugwithdrawal in clinical renal allotransplantation. Transplantation 84, 1215-1219.
10. Azimzadeh, A. M., Pfeiffer, S., Wu, G., Schroder, C., Zorn, G. L. III, Kelishadi, S. S., Ozkaynak, E., Kehry, M., Atkinson, J. B., Miller, G. G., and Pierson, R. N. III, (2006). Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms. Transplantation 81, 255-264.
11. Badell, I. R., Russell, M. C., Thompson,P.W.,Turner,A. P.,Weaver,T.A., Robertson, J. M., Avila, J. G., Cano, J. A., Johnson, B. E., Song, M., Leopardi, F. V., Swygert, S., Strobert, E. A., Ford, M. L., Kirk, A. D., and Larsen, C. P. (2010). LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J. Clin. Invest. 120, 4520-4531.
12. Badell, I. R., Thompson, P. W., Turner, A.P.,Russell,M.C.,Avila,J.G.,Cano, J. A., Robertson, J. M., Leopardi, F. V., Strobert, E. A., Iwakoshi, N. N., Reimann, K. A., Ford, M. L., Kirk, A. D., and Larsen, C. P. (2012). Non-depleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am. J. Transplant. 12, 126-135.
13. Battaglia, M., Stabilini, A., Migliavacca, B.,Horejs-Hoeck,J.,Kaupper,T.,and Roncarolo, M. G. (2006). Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177,8338-8347.
14. Beiras-Fernandez, A., Chappell, D., Hammer, C., Beiras, A., Reichart, B., and Thein, E. (2009). Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transpl. Immunol. 20, 224-228.
15. Billingham, R. E., Brent, L., and Medawar, P. B. (1953). Actively acquired tolerance of foreign cells. Nature 172,603-606.
16. Bloom, D., Chang, Z., Pauly, K., Kwun, J., Fechner, J., Hayes, C., Samaniego, M., and Knechtle, S. (2009). BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am. J. Transplant. 9,1835-1845.
17. Bluestone, J. A. (2005). Regulatory T- cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5, 343-349.
18. Bluestone, J. A., Auchincloss, H., Nepom, G. T., Rotrosen, D., St Clair, E. W., and Turka, L. A. (2010). The immune tolerance network at 10 years: tolerance research at the bedside. Nat. Rev. Immunol. 10, 797-803.
19. Bluestone, J. A., Thomson, A. W., Shevach,E.M.,andWeiner,H.L.(2007). What does the future hold for cellbased tolerogenic therapy? Nat. Rev. Immunol. 7,650-654.
20. Bohne, F., Martinez-Llordella, M., Lozano, J. J., Miquel, R., Benitez, C., Londono, M. C., Manzia, T. M., Angelico, R., Swinkels, D. W., Tjalsma, H., Lopez, M., Abraldes, J. G., Bonaccorsi-Riani, E., Jaeckel, E., Taubert, R., Pirenne, J., Rimola, A., Tisone, G., and Sanchez-Fueyo, A. (2012). Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J. Clin. Invest. 122, 368-382.
21. Boks, M. A., Kager-Groenland, J. R., Haasjes, M. S., Zwaginga, J. J., Van Ham, S. M., and Ten Brinke, A. (2012). IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction - a comparativestudyof humanclinical- applicable DC. Clin. Immunol. 142, 332-342.
22. Brem-Exner, B. G., Sattler, C., Hutchinson, J. A., Koehl, G. E., Kronenberg, K., Farkas, S., Inoue, S., Blank, C., Knechtle, S. J., Schlitt, H. J., Fandrich, F., and Geissler, E. K. (2008). Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J. Immunol. 180, 335-349.
23. Brennan, T. V., Tang, Q., Liu, F. C., Hoang,V.,Bi,M.,Bluestone,J.A.,and Kang, S. M. (2011). Requirements for prolongation of allograft survival with regulatory T cell in fusion in lympho sufficient hosts. J. Surg. Res. 169, e69-e75.
24. Brenner, M. J., Jensen, J. N., Lowe, J. B. III, Myckatyn, T. M., Fox, I. K., Hunter,D.A.,Mohanakumar,T.,and Mackinnon, S. E. (2004). Anti-CD40 ligandantibodypermitsregeneration throughperipheralnerveallograftsin a nonhuman primate model. Plast. Reconstr. Surg. 114, 1802-1814; discussion 1815-1807.
25. Brunstein, C. G., Miller, J. S., Cao, Q., Mckenna, D. H., Hippen, K. L., Curtsinger, J., Defor, T., Levine, B. L., June, C. H., Rubinstein, P., Mcglave, P. B., Blazar, B. R., and Wagner, J. E. (2011). Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117, 1061-1070.
26. Brusko, T. M., Koya, R. C., Zhu, S., Lee, M. R., Putnam, A. L., Mcclymont, S. A., Nishimura, M. I., Han, S., Chang, L. J., Atkinson, M. A., Ribas, A., and Bluestone, J. A. (2010). Human antigen-specific regulatory T cellsgeneratedbyTcellreceptorgene transfer. PLoS ONE 5,e11726.
27. Bunnapradist, S., and Takemoto, S. K. (2005). Multivariate analysis of antibodyinductiontherapyandtheir associated outcomes in deceased donor transplants. Transplant. Proc. 37,889-891.
28. Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., and Bennett, C. L. (2009). Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a ReviewfromtheResearchonAdverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10,816-824.
29. Cecka, J. M., Gjertson, D., and Terasaki, P. I. (1993). Do prophylacticantilymphocyteglobulins(ALG and OKT3) improve renal transplant survival in recipient and donor highrisk groups? Transplant. Proc. 25, 548-549.
30. Chappell, D., Beiras-Fernandez, A., Hammer, C., and Thein, E. (2006). In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 81, 552-558.
31. Cohen, J. L., Trenado, A., Vasey, D., Klatzmann, D., and Salomon, B. L. (2002). CD4(+)CD25(+) immunoregulatoryTCells:newtherapeuticsforgraft-versus-hostdisease. J. Exp. Med. 196,401-406.
32. Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., and Vignali, D. A. (2007). The inhibitorycytokineIL-35contributes to regulatory T-cell function. Nature 450, 566-569.
33. Colson, Y. L., Wren, S. M., Schuchert, M. J., Patrene, K. D., Johnson, P. C., Boggs, S. S., and Ildstad, S. T. (1995). A nonlethal conditioning approachtoachievedurablemultilineage mixed chimerism and tolerance across major,minor,and hematopoietic histocompatibility barriers. J. Immunol. 155,4179-4188.
34. Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., Del Papa, B., Zei, T., Ostini, R. I., Cecchini, D., Aloisi, T., Perruccio, K., Ruggeri, L., Balucani, C., Pierini, A., Sportoletti, P., Aristei, C., Falini, B., Reisner, Y., Velardi, A., Aversa, F., and Martelli, M. F. (2011). Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928.
35. Duijvestein, M., Molendijk, I., Roelofs, H.,Vos,A.C.,Verhaar,A.P.,Reinders, M. E., Fibbe, W. E.,Verspaget, H. W., VanDenBrink,G.R.,Wildenberg,M. E., and Hommes, D. W. (2011). Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy 13, 1066-1073.
36. Edinger, M., and Hoffmann, P. (2011). Regulatory T cells in stem cell transplantation:strategiesandfirstclinical experiences. Curr. Opin. Immunol. 23,679-684.
37. Eggers, P. W. (1988). Effect of transplantationontheMedicareend-stage renal disease program. N. Engl. J. Med. 318,223-229.
38. EMD Serono. (2011). Atacicept in multiple sclerosis,Phase II.
39. Eng, H. S., Bennett, G., Tsiopelas, E., Lake, M., Humphreys, I., Chang, S. H., Coates, P. T., and Russ, G. R. (2008). Anti-HLA donor-specific antibodies detected in positive BcellcrossmatchesbyLuminexpredict late graft loss. Am. J. Transplant. 8, 2335-2342.
40. Fandrich, F., Lin, X., Chai, G. X., Schulze, M., Ganten, D., Bader, M., Holle, J., Huang, D. S., Parwaresch, R., Zavazava, N., and Binas, B. (2002). Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat. Med. 8, 171-178.
41. Fujita, S., Sato, Y., Sato, K., Eizumi, K., Fukaya, T., Kubo, M., and Yamashita, N. (2007). Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+ CD25+ Foxp3+ regulatoryTcells.Blood110,3793-3803.
42. Gaber, A. O., Monaco, A. P., Russell, J. A., Lebranchu, Y., and Mohty, M. (2010). Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 70, 691-732.
43. Godfrey, W. R., Ge, Y. G., Spoden, D. J., Levine, B. L., June, C. H., Blazar, B. R., and Porter, S. B. (2004). In vitro-expanded human CD4(+)CD25(+)T-regulatorycells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104, 453-461.
44. Golshayan, D., Jiang, S., Tsang, J., Garin, M. I., Mottet, C., and Lechler, R. I. (2007). In vitro-expanded donor alloantigen-specific CD4+CD25+regulatoryTcellspromote experimental transplantation tolerance. Blood 109, 827-835.
45. Graca, L., Cobbold, S. P., and Waldmann, H. (2002). Identification of regulatory T cells in tolerated allografts. J. Exp. Med. 195,1641-1646.
46. Guthoff, M., Schmid-Horch, B., Weisel, K.C.,Haring,H.U.,Konigsrainer,A., and Heyne, N. (2012). Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl. Immunol. 26, 171-175.
47. Hamawy, M. M., and Knechtle, S. J. (1998). Strategies for tolerance induction in nonhuman primates. Curr. Opin. Immunol. 10,513-517.
48. Hanaway, M. J., Woodle, E. S., Mulgaonkar,S.,Peddi,V. R.,Kaufman,D. B.,First,M.R.,Croy,R.,andHolman, J. (2011). Alemtuzumab induction in renaltransplantation.N.Engl.J.Med. 364,1909-1919.
49. Hering, B. J., Wijkstrom, M., Graham, M. L., Hardstedt, M., Aasheim, T. C., Jie, T., Ansite, J. D., Nakano, M., Cheng, J., Li, W., Moran, K., Christians, U., Finnegan, C., Mills, C. D., Sutherland, D. E., Bansal-Pakala,P.,Murtaugh,M.P.,Kirchhof, N., and Schuurman, H. J. (2006). Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat. Med. 12,301-303.
50. HHS/HRSA/HSB/DOT. (2009). Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Rockville,MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
51. Hippen, K. L., Merkel, S. C., Schirm, D. K., Sieben, C. M., Sumstad, D., Kadidlo, D. M., Mckenna, D. H., Bromberg, J. S., Levine, B. L., Riley, J. L.,June,C.H.,Scheinberg,P.,Douek, D. C., Miller, J. S., Wagner, J. E., and Blazar, B. R. (2011). Massive ex vivo expansion of human natural regulatory T cells (T (regs)) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3,83ra41.
52. Hodges, A. M., Lyster, H., Mcdermott, A., Rice, A. J., Smith, J. D., Rose, M. L., and Banner, N. R. (2012). Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 93, 650-6.
53. Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R., and Edinger, M. (2004). Largescale in vitro expansion of polyclonal human CD4(+) CD25high regulatoryTcells.Blood 104,895-903.
54. Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061.
55. Hutchinson, J. A., Brem-Exner, B. G., Riquelme, P., Roelen, D., Schulze, M., Ivens, K., Grabensee, B., Witzke, O., Philipp, T., Renders, L., Humpe, A., Sotnikova, A., Matthai, M., Heumann, A., Govert, F., Schulte, T., Kabelitz, D., Claas, F. H., Geissler, E. K., Kunzendorf, U., and Fandrich, F. (2008a). A cell-based approach to the minimization of immuno-suppression in renal transplantation. Transpl. Int. 21,742-754.
56. Hutchinson, J. A., Riquelme, P., Brem-Exner, B. G., Schulze, M., Matthai, M., Renders, L., Kunzendorf, U., Geissler, E. K., and Fandrich, F. (2008b). Transplant acceptanceinducing cells as an immune- conditioning therapy in renal transplantation. Transpl. Int. 21, 728-741.
57. Ildstad, S. T., and Sachs, D. H. (1984). Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307, 168-170.
58. Jackson, A. M., and Zachary, A. A. (2008).Theproblemoftransplanting thesensitizedpatient:whoseproblem is it? Front. Biosci. 13,1396-1412.
59. Jankowski, R. A., and Ildstad, S. T. (1997). Chimerism and tolerance: from freemartin cattle and neonatal mice to humans. Hum. Immunol. 52, 155-161.
60. Jenkins, M. K., and Schwartz, R. H. (1987). Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165,302-319.
61. Joffre, O., Santolaria, T., Calise, D., Al Saati, T., Hudrisier, D., Romagnoli, P., and Van Meerwijk, J. P. (2008). Prevention of acute and chronic allograft rejection with CD4+ CD25+ Foxp3+ regulatory T lymphocytes. Nat. Med. 14,88-92.
62. Jordan, S. C., and Pescovitz, M. D. (2006). Presensitization: the problem and its management. Clin. J.Am. Soc. Nephrol. 1,421-432.
63. Karlsson,H.,Erkers,T.,Nava,S.,Ruhm, S., Westgren, M., and Ringden, O. (2012). Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin. Exp. Immunol. 167,543-555.
64. Kasiske, B. L., Zeier, M. G., Chapman, J. R., Craig, J. C., Ekberg, H., Garvey, C. A., Green, M. D., Jha, V., Josephson, M. A., Kiberd, B. A., Kreis, H. A., Mcdonald, R. A., Newmann, J. M., Obrador, G. T., Vincenti, F. G., Cheung, M., Earley, A., Raman, G., Abariga, S., Wagner, M., and Balk, E. M. (2010). KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 77, 299-311.
65. Kaufman,C.L.,andIldstad,S.T.(1994). Inductionofdonor-specifictolerance by transplantation of bone marrow. Ther. Immunol. 1,101-111.
66. Kawai, T., Cosimi, A. B., Colvin, R. B., Powelson, J., Eason, J., Kozlowski, T., Sykes, M., Monroy, R., Tanaka, M., and Sachs, D. H. (1995). Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 59, 256-262.
67. Kawai, T., Cosimi, A. B., and Sachs, D. H. (2011). Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr. Opin. Organ Transplant. 16, 366-371.
68. Kawai, T., Cosimi, A. B., Spitzer, T. R., Tolkoff-Rubin, N., Suthanthiran, M., Saidman, S. L., Shaffer, J., Preffer, F. I., Ding, R., Sharma, V., Fishman, J. A., Dey, B., Ko, D. S., Hertl, M., Goes, N. B., Wong, W., Williams, W. W. Jr., Colvin, R. B., Sykes, M., and Sachs, D. H. (2008). HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353-361.
69. Kawai, T., Sogawa, H., Boskovic, S., Abrahamian, G., Smith, R. N., Wee, S. L., Andrews, D., Nadazdin, O., Koyama, I., Sykes, M., Winn, H. J., Colvin, R. B., Sachs, D. H., and Cosimi, A. B. (2004). CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am. J. Transplant. 4, 1391- 1398.
70. Kelishadi, S. S., Azimzadeh, A. M., Zhang, T., Stoddard, T., Welty, E., Avon, C., Higuchi, M., Laaris, A., Cheng, X. F., Mcmahon, C., and Pierson, R. N. III. (2010). Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J. Clin. Invest. 120,1275-1284.
71. Kirk, A. D., Burkly, L. C., Batty, D. S., Baumgartner, R. E., Berning, J. D., Buchanan, K., Fechner, J. H. Jr., Germond, R. L., Kampen, R. L., Patterson, N. B., Swanson, S. J., Tadaki, D. K., Tenhoor, C. N., White, L., Knechtle, S. J., and Harlan, D. M. (1999). Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5,686-693.
72. Kirk, A. D., Harlan, D. M., Armstrong, N. N., Davis, T. A., Dong, Y., Gray, G. S., Hong, X., Thomas, D., Fechner, J. H. Jr., and Knechtle, S. J. (1997).CTLA4-Igandanti-CD40ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U. S. A. 94,8789-8794.
73. Knechtle, S. J., and Burlingham, W. J. (2004). Metastable tolerance in nonhuman primates and humans. Transplantation 77, 936-939.
74. Knechtle, S. J., Fernandez, L. A., Pirsch, J. D., Becker, B. N., Chin, L.T.,Becker,Y.T.,Odorico,J.S., D'Alessandro, A, M., and Sollinger, H. W. (2004). Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 136, 754-760.
75. Knechtle, S. J., Pascual, J., Bloom, D. D., Torrealba, J. R., Jankowska-Gan, E., Burlingham, W. J., Kwun, J., Colvin, R. B., Seyfert-Margolis, V., Bourcier, K., and Sollinger, H. W. (2009). Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical resultsandimmunemonitoring.Am. J. Transplant. 9,1087-1098.
76. Knechtle,S.J.,Pirsch,J.D.,H.FechnerJ. Jr.,Becker,B.N.,Friedl,A.,Colvin,R. B., Lebeck, L. K., Chin, L. T., Becker, Y. T., Odorico, J. S., D'Alessandro, A. M., Kalayoglu, M., Hamawy, M. M., Hu, H., Bloom, D. D., and Sollinger,H.W.(2003).Campath-1H inductionplusrapamycinmonotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 3, 722-730.
77. Knechtle, S. J., Vargo, D., Fechner, J., Zhai, Y., Wang, J., Hanaway, M. J., Scharff, J., Hu, H., Knapp, L., Watkins, D., and Neville, D. M. Jr. (1997). FN18-CRM9 immuno- toxin promotes tolerance in primaterenalallografts.Transplantation 63,1-6.
78. Kopchaliiska, D., Zachary, A. A., Montgomery, R. A., and Leffell, M. S. (2009). Reconstitution of peripheralallospecificCD19+B-cellsubsets afterB-lymphocytedepletiontherapy in renal transplant patients. Transplantation 87,1394-1401.
79. Koreth, J., Matsuoka, K., Kim, H. T., Mcdonough, S. M., Bindra, B.,Alyea, E. P. III, Armand, P., Cutler, C., Ho, V. T., Treister, N. S., Bienfang, D. C., Prasad,S.,Tzachanis,D.,Joyce,R.M., Avigan, D. E., Antin, J. H., Ritz, J., andSoiffer,R.J.(2011).Interleukin-2 andregulatoryTcellsingraft-versushost disease. N. Engl. J. Med. 365, 2055-2066.
80. Koyama, I., Kawai, T., Andrews, D., Boskovic, S., Nadazdin, O., Wee, S. L., Sogawa, H., Wu, D. L., Smith, R. N., Colvin, R. B., Sachs, D. H., and Cosimi, A. B. (2004). Thrombophilia associated with anti- CD154 monoclonal antibody treatment and its prophylaxis in non- human primates. Transplantation 77, 460-462.
81. Kozlowski, T., and Andreoni, K. (2011). Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann. Transplant. 16, 19-25.
82. Kwun, J., and Knechtle, S. J. (2009). Overcoming Chronic Rejection-Can it B? Transplantation 88, 955-961.
83. Larsen, C. P., Grinyo, J., Medina-Pestana, J., Vanrenterghem, Y., Vincenti, F., Breshahan, B., Campistol, J. M., Florman, S., Rial Mdel, C., Kamar, N., Block, A., Di Russo, G., Lin, C. S., Garg, P., and Charpentier, B. (2010). Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 90, 1528-1535.
84. Larsen, C. P., Knechtle, S. J., Adams, A., Pearson, T., and Kirk, A. D. (2006). A new look at blockade of T-cell costimulation: a therapeutic strategy forlong-termmaintenanceimmunosuppression. Am. J. Transplant. 6, 876-883.
85. Larsen, C. P., Pearson, T. C., Adams, A. B., Tso, P., Shirasugi, N., Strobert, E., Anderson, D., Cowan, S., Price, K., Naemura, J., Emswiler, J., Greene, J., Turk, L. A., Bajorath, J., Townsend, R., Hagerty, D., Linsley, P. S., and Peach, R. J. (2005). Rational developmentofLEA29Y(belatacept), a high-affinity variant of CTLA4- Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453.
86. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., Dini, G., Egeler, R. M., Bacigalupo, A., Fibbe, W., and Ringden, O. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graftversus-host disease: a phase II study. Lancet 371,1579-1586.
87. Lee, P. C., Zhu, L., Terasaki, P. I., and Everly, M. J. (2009). HLA- specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88, 568-574.
88. Lefaucheur, C., Suberbielle-Boissel, C., Hill, G. S., Nochy, D., Andrade, J., Antoine, C., Gautreau, C., Charron, D., and Glotz, D. (2008). Clinical relevance of preformed HLA donor- specific antibodies in kidney transplantation. Am. J. Transplant. 8, 324-331.
89. Leslie,M.(2011).Immunology.Regulatory T cells get their chance to shine. Science 332,1020-1021.
90. Levings, M. K., Sangregorio, R., and Roncarolo, M. G. (2001). Human cd25 (+)cd4 (+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193,1295-1302.
91. Levitsky, J. (2011). Operational tolerance: past lessons and future prospects. Liver Transpl. 17, 222-232.
92. Li, L., Wozniak, L. J., Rodder, S., Heish, S., Talisetti, A., Wang, Q., Esquivel, C., Cox, K., Chen, R., Mcdiarmid, S. V., and Sarwal, M. M. (2012). A common peripheral blood gene set fordiagnosisof operationaltolerance in pediatric and adult liver transplantation. Am. J. Transplant. 12, 1218-1228.
93. Li,Y.,Li,X.C.,Zheng,X.X.,Wells,A.D., Turka, L. A., and Strom, T. B. (1999). Blockingbothsignal1andsignal2of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allografttolerance. Nat. Med. 5,1298-1302.
94. Liu, C., Noorchashm, H., Sutter, J. A., Naji, M., Prak, E. L., Boyer, J., Green, T., Rickels, M. R., Tomaszewski, J. E., Koeberlein, B.,Wang, Z., Paessler, M. E.,Velidedeoglu,E.,Rostami,S.Y.,Yu, M., Barker, C. F., and Naji,A. (2007). Blymphocyte-directedimmunotherapy promotes long-term islet allograftsurvivalinnonhumanprimates. Nat. Med. 13,1295-1298.
95. Lopez, M., Clarkson, M. R., Albin, M., Sayegh, M. H., and Najafian, N. (2006). A novel mechanism of action for anti-thymocyte globulin: induction of CD4+ CD25+ Foxp3+ regulatoryTcells.J.Am.Soc.Nephrol. 17, 2844-2853.
96. Mackay, F., Schneider, P., Rennert, P., and Browning, J. (2003). BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264.
97. Magliocca, J. F., and Knechtle, S. J. (2006). The evolving role of alemtuzumab (Campath-1H) for immunosuppressivetherapyinorgan transplantation. Transpl. Int. 19, 705-714.
98. Malek, T. R. (2008). The biology of interleukin-2. Annu. Rev. Immunol. 26, 453-479.
99. Markmann, J. (2011). Immunosuppression with antithymocyte globulin, rituximab,tacrolimus,andsirolimus,followedbywithdrawaloftacrolimusand sirolimus, in living-donor renal transplant recipients. National Institute of Allergy and Infectious Diseases (NIAID). ClinicalTrials.gov identifier: NCT01318915. Bethesda, MD: National Library of Medicine.
100. Masteller, E. L., Warner, M. R., Tang, Q., Tarbell, K. V., Mcdevitt, H., and Bluestone, J. A. (2005). Expansion of functional endogenous antigen-specific CD4+ CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol. 175, 3053-3059.
101. Matthews, J. B., Ramos, E., and Blue-stone, J. A. (2003). Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. 3, 794-803.
102. Meier-Kriesche, H. U., Schold, J. D., and Kaplan, B. (2004). Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am. J. Transplant. 4, 1289-1295.
103. Michallet, M. C., Preville, X., Flacher, M., Fournel, S., Gen-estier, L., and Revillard, J. P. (2003). Functional antibodies to leukocyte adhesion molecules in antithymo-cyte globulins. Transplantation 75, 657-662.
104. Morrow, W. R., Frazier, E. A., Mahle, W. T., Harville, T. O., Pye, S. E., Knecht, K. R., Howard, E. L., Smith, R. N., Saylors, R. L., Garcia, X., Jaquiss, R. D., and Woo-dle, E. S. (2012). Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93, 319-324.
105. Munn, D. H., Sharma, M. D., and Mellor, A. L. (2004). Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110.
106. Munoz, A. S., Rioveros, A. A., Cabanayan-Casasola, C. B., Dan-guilan, R. A., and Ona, E. T. (2008). Rituximab in highly sensitized kidney transplant recipients. Transplant. Proc. 40, 2218-2221.
107. Nagahama, K., Nishimura, E., and Sakaguchi, S. (2007). Induction of tolerance by adoptive transfer of Treg cells. Methods Mol. Biol. 380, 431-442.
108. Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., and Strober, W. (2004). TGF-beta 1 plays an important role in the mechanism of CD4+ CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842.
109. Nanda, S. (2011). Therapy: Atacicept lacks clinical efficacy in RA. Nat. Rev. Rheumatol. 7, 313.
110. Nelson, B. H. (2004). IL-2, regulatory T cells, and tolerance. J. Immunol. 172, 3983-3988.
111. Newell, K. A., Asare, A., Kirk, A. D., Gisler, T. D., Bourcier, K., Suthanthi-ran, M., Burlingham, W. J., Marks, W. H., Sanz, I., Lechler, R. I. Hernandez-Fuentes, M. P., Turka, L. A., and Seyfert-Margolis, V. L. (2010). Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836-1847.
112. Nishimura, E., Sakihama, T., Setoguchi, R., Tanaka, K., and Sakaguchi, S. (2004). Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+ CD25+ CD4+regulatory T cells. Int. Immunol. 16, 1189-1201.
113. O'Garra, A., and Vieira, P. (2004). Regulatory T cells and mechanisms of immune system control. Nat. Med. 10, 801-805.
114. Orlando, G., Hematti, P., Stratta, R. J., Burke, G. W. III, Di Cocco, P., Pisani, F., Soker, S., and Wood, K. (2010). Clinical operational tolerance after renal transplantation: current status and future challenges. Ann. Surg. 252, 915-928.
115. Orlando, G., Soker, S., and Wood, K. (2009). Operational tolerance after liver transplantation. J. Hepatol. 50, 1247-1257.
116. Otten, H. G., Verhaar, M. C., Borst, H. P.E., Hene, R. J., and Van Zuilen, A. D. (2012). Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk of kidney graft failure. Am. J. Transplant. 12.
117. Owen, R. D. (1945). Immunogenetic consequences of vascular anastomoses between bovine twins. Science 102, 400-401.
118. Patel, J., Everly, M., Chang, D., Kittleson, M., Reed, E., and Kobashigawa, J. (2011). Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J. Heart Lung Transplant. 30, 1320-1326.
119. Pearl, J. P., Parris, J., Hale, D. A., Hoffmann, S. C., Bernstein, W. B., Mccoy, K. L., Swanson, S. J., Mannon, R. B., Roederer, M., and Kirk, A. D. (2005). Immunocom-petent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am. J. Transplant. 5, 465-474.
120. Pearl, J. P., Xu, H., Leopardi, F., Preston, E., and Kirk, A. D. (2007). CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cynomol-gus monkeys despite homeostatic T-cell activation. Transplantation 83, 1219-1225.
121. Pearson, T. C., Trambley, J., Odom, K., Anderson, D. C., Cowan, S., Bray, R., Lin, A., Hollenbaugh, D., Aruffo, A., Siadak, A. W., Strobert,E.,Hennigar,R.,andLarsen, C. P. (2002). Anti-CD40 therapy extendsrenalallograftsurvivalinrhesus macaques. Transplantation 74, 933-940.
122. Pestana, J. O., Grinyo, J. M., Vanrenterghem,Y.,Becker,T.,Campistol, J. M., Florman, S., Garcia, V. D., Kamar, N., Lang, P., Manfro, R. C., Massari, P., Rial, M. D., Schnitzler, M. A., Vitko, S., Duan, T., Block, A., Harler, M. B., and Durrbach, A. (2012). Three-year outcomes from BENEFIT-EXT: a phase III study of Belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12, 630-639.
123. Pu, L. Y., Wang, X. H., Zhang, F., Li, X. C.,Yao,A. H.,Yu,Y., Lv, L., and Li, G.Q.(2007).Adoptivetransfusionof ex vivo donor alloantigen-stimulated CD4 (+)CD25 (+) regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation. Surgery 142, 67-73.
124. Rabinovitch, A., Suarez-Pinzon, W. L., Shapiro, A. M., Rajotte, R. V., and Power, R. (2002). Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51,638-645.
125. Ramos, E. J., Pollinger, H. S., Stegall, M. D., Gloor, J. M., Dogan, A., and Grande, J. P. (2007). The effect of desensitization protocols on human splenic B-cell populationsinvivo.Am. J. Transplant. 7, 402-407.
126. Rayfield, L. S., and Brent, L. (1983). Tolerance, immunocompetence, and secondary disease in fully allogeneic radiation chimeras. Transplantation 36,183-189.
127. Redfield, R. R. III, Rodriguez, E., Parsons, R., Vivek, K., Mustafa, M. M., Noorchashm,H.,andNaji,A.(2011). Essential role for B cells in transplantation tolerance. Curr. Opin. Immunol. 23, 685-691.
128. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski,R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348,2609-2617.
129. Ruedi, E., Sykes, M., Ildstad, S. T., Chester, C. H., Althage, A., Hengartner,H.,Sachs,D.H.,andZinkernagel, R. M. (1989). Antiviral T cell competence and restriction specificityof mixed allogeneic (P1+ P2----P1) irradiation chimeras. Cell. Immunol. 121,185-195.
130. Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., and Klatzmann, D. (2011). Regulatory T-cell responses to low-dose interleukin-2 in HCV- induced vasculitis. N. Engl. J. Med. 365,2067-2077.
131. Sachs, D. H., Sykes, M., Kawai, T., and Cosimi, A. B. (2011). Immunointervention for the induction of transplantation tolerance through mixed chimerism. Semin. Immunol. 23, 165-173.
132. Sagoo, P., Perucha, E., Sawitzki, B., Tomiuk, S., Stephens, D. A., Miqueu, P., Chapman, S., Craciun, L., Sergeant, R., Brouard, S., Rovis, F., Jimenez, E., Ballow, A., Giral, M., Rebollo-Mesa, I., Le Moine, A., Braudeau,C.,Hilton,R.,Gerstmayer, B., Bourcier, K., Sharif, A., Krajewska, M., Lord, G. M., Roberts, I., Goldman, M., Wood, K. J., Newell, K., Seyfert-Margolis, V., Warrens, A. N., Janssen, U., Volk, H. D., Soulillou, J. P., Hernandez-Fuentes, M. P., and Lechler, R. I. (2010). Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120,1848-1861.
133. Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M. T., Shizuru, J. A., Lowsky, R., Engleman, E. G., and Strober, S. (2012). Tolerance and withdrawal of immunosuppressivedrugsinpatients given kidney and hematopoietic cell transplants. Am. J. Transplant. 12, 1133-1145.
134. Schneider, P., Mackay, F., Steiner, V., Hofmann, K., Bodmer, J. L., Holler, N., Ambrose, C., Lawton, P., Bixler, S., Acha-Orbea, H., Valmori, D., Romero,P.,Werner-Favre,C.,Zubler, R. H., Browning, J. L., and Tschopp, J. (1999). BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189, 1747-1756.
135. Schwartz,R.,andDameshek,W.(1959). Drug-induced immunological tolerance. Nature 183,1682-1683.
136. Schwartz, R. H. (1990). A cell culture model for T lymphocyte clonal anergy. Science 248, 1349-1356.
137. Shapiro, A. M., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., Cagliero, E., Alejandro, R., Ryan, E. A., Dimercurio, B., Morel, P., Polonsky, K. S., Reems, J. A., Bretzel, R. G., Bertuzzi, F., Froud, T., Kandaswamy, R., Sutherland, D. E., Eisenbarth, G., Segal, M., Preiksaitis, J., Korbutt, G. S., Barton, F. B., Viviano, L., Seyfert-Margolis,V., Bluestone, J., and Lakey, J. R. (2006). International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355, 1318-1330.
138. Sharabi, Y., and Sachs, D. H. (1989). Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J. Exp. Med. 169,493-502.
139. Shield, C. F., Edwards, E. B., Davies, D. B., and Daily, O. P. (1997). Antilym- phocyteinductiontherapyincadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study. Transplantation 63,1257-1263.
140. Shimony, O., Nagler, A., Gellman, Y. N., Refaeli, E., Rosenblum, N., Eshkar-Sebban, L., Yerushalmi, R., Shimoni, A., Lytton, S. D., Stanevsky, A., Or, R., and Naor, D. (2012). Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J. Clin. Immunol. 32, 173-188.
141. Singer, N. G., and Caplan, A. I. (2011). Mesenchymalstemcells:mechanisms of inflammation. Annu. Rev. Pathol. 6, 457-478.
142. Singh, K., Kozyr, N., Stempora, L., Kirk, A. D., Larsen, C. P., Blazar, B. R., and Kean, L. S. (2012). Regulatory Tcellsexhibitdecreasedproliferation but enhanced suppression after pulsing with sirolimus. Am. J. Transplant. 12,1441-1457.
143. Solari, M. G., Srinivasan, S., Boumaza, I., Unadkat, J., Harb, G., Garcia-Ocana, A., and Feili-Hariri, M. (2009). Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J. Autoimmun. 32, 116-124.
144. Spitzer, T. R., Sykes, M., Tolkoff-Rubin, N., Kawai, T., Mcafee, S. L., Dey, B. R., Ballen, K., Delmonico, F., Saidman, S., Sachs, D. H., and Cosimi, A. B. (2011). Long-term follow-up of recipientsofcombinedhumanleukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 91, 672-676.
145. Starzl, T. E., Marchioro, T. L., and Waddell, W. R. (1963). The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg. Gynecol. Obstet. 117, 385-395.
146. Strober, S., Dhillon, M., Schubert, M., Holm, B., Engleman, E., Benike, C., Hoppe, R., Sibley, R., Myburgh, J. A. and Collins, G. (1989). Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N. Engl. J. Med. 321, 28-33.
147. Stuckey, L. J., Kamoun, M., and Chan, K. M. (2012). Lung transplantationacrossdonor-specificantihuman leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Ann. Pharmacother. 46,e2.
148. Sureshkumar, K. K., Hussain, S. M., Marcus, R. J., Ko, T. Y., Khan, A. S., Tom, K., Vivas, C. A., Parris, G., Jasnosz, K. M., and Thai, N. L. (2012). Proteasome inhibition withbortezomib:aneffectivetherapy for severe antibody mediated rejection after renal transplantation. Clin. Nephrol. 77, 246-253.
149. Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., and Bluestone, J. A. (2008). Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697.
150. Taylor, P. A., Lees, C. J., and Blazar, B. R. (2002). The infusion of ex vivo activated and expanded CD4 (+)CD25 (+) immune regulatory cellsinhibitsgraft-versus-hostdisease lethality. Blood 99, 3493-3499.
151. Terasaki, P., Lachmann, N., and Cai, J. (2006). Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin. Transpl., 455-462.
152. Terasaki, P. I., and Cai, J. (2008). Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 86, 377-383.
153. Thompson, P., Cardona, K., Russell, M., Badell, I. R., Shaffer, V., Korbutt, G., Rayat, G. R., Cano, J., Song, M., Jiang, W., Strobert, E., Rajotte, R., Pearson, T., Kirk, A. D., and Larsen, C. P. (2011). CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am. J. Transplant. 11, 947-957.
154. Thompson, S. A., Jones, J. L., Cox, A. L., Compston, D. A., and Coles, A. J. (2010). B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 30, 99-105.
155. Thomson, A. W., Turnquist, H. R., Zahorchak, A. F., and Raimondi, G. (2009). Tolerogenic dendritic cellregulatory T-cell interaction and the promotion of transplant tolerance. Transplantation 87,S86-90.
156. Torrealba, J. R., Fernandez, L. A., Kanmaz, T., Oberley, T. D., Schultz, J. M., Brunner, K. G., Peters, D., Fechner, J. H. Jr., Dong, Y., Hu, H., Hamawy, M. M., and Knechtle, S. J. (2003). Immunotoxin-treated rhesus monkeys: a model for renal allograft chronicrejection.Transplantation76, 524-530.
157. Torrealba, J. R., Katayama, M., Fechner, J. H. Jr., Jankowska-Gan, E., Kusaka, S., Xu, Q., Schultz, J. M., Oberley, T. D., Hu, H., Hamawy, M. M., Jonker, M., Wubben, J., Doxiadis, G., Bontrop, R., Burlingham, W. J., and Knechtle, S. J. (2004). Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+ CD4+ T regulatory cell infiltrates. J. Immunol. 172,5753-5764.
158. Trenado, A., Sudres, M., Tang, Q., Maury, S., Charlotte, F., Gregoire, S., Bonyhadi, M., Klatzmann, D., Salomon, B. L., and Cohen, J. L. (2006). Ex vivo-expanded CD4+ CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J. Immunol. 176,1266-1273.
159. Trzonkowski, P., Zilvetti, M., Chapman, S., Wieckiewicz, J., Sutherland, A., Friend, P., and Wood, K. J. (2008). Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depletedkidneytransplant recipients treated with reduced immunosuppression. Am. J. Transplant. 8, 338-347.
160. Tsang,J.Y.,Tanriver,Y.,Jiang,S.,Leung, E., Ratnasothy, K., Lombardi, G., and Lechler, R. (2009). Indefinite mouse heart allograft survival in recipient treated with CD4 (+)CD25 (+)regulatoryTcellswithindirectallospecificity and short term immunosuppression. Transpl. Immunol. 21, 203-209.
161. Turgeon, N. A., Avila, J. G., Cano, J. A., Hutchinson, J. J., Badell, I. R., Page, A. J., Adams, A. B., Sears, M. H., Bowen, P. H., Kirk, A. D., Pearson, T. C., and Larsen, C. P. (2010). Experience with a novel efalizumab-based immunosuppressiveregimentofacilitate single donor islet cell transplantation. Am. J. Transplant. 10, 2082-2091.
162. Turnquist, H. R., Raimondi, G., Zahorchak, A. F., Fischer, R. T., Wang, Z., and Thomson, A. W. (2007). Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplanttolerance.J.Immunol.178, 7018-7031.
163. van Kooten, C., and Banchereau, J. (1997a).FunctionalroleofCD40and itsligand.Int.Arch.Allergy.Immunol. 113,393-399.
164. van Kooten, C., and Banchereau, J. (1997b). Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9,330-337.
165. Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyo, J., Neumayer, H. H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., and Vincenti, F. (2011). Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91,976-983.
166. Vermeiren, J., Ceuppens, J. L., Van Ghelue, M., Witters, P., Bullens, D., Mages, H. W., Kroczek, R. A., and Van Gool, S. W. (2004). Human T cell activation by costimulatorysignal-deficientallogeneic cells induces inducible costimulatorexpressing anergic T cells with regulatory cell activity. J. Immunol. 172, 5371-5378.
167. Vieira, P. L., Christensen, J. R., Minaee, S., O'Neill, E. J., Barrat, F. J., Boonstra, A., Barthlott, T., Stockinger, B., Wraith, D. C., and O'Garra, A. (2004). IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+ CD25+ regulatory T cells. J. Immunol. 172, 5986-5993.
168. Vivek, K., Parsons, R., Rostami, S. Y., Mustafa, M. M., Rodriguez, E., Redfield, R. R., Luo, Y., Ziaie, A. S., Migone, T. S., Cancro, M. P., Naji, A., and Noorchashm, H. (2011). BLyS-directed immunotherapy purges alloreactive specificities from the primary B-cell repertoire and promotes humoral transplantation tolerance. Am. J. Transplant. 11, 171 (Abstract #470).
169. Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C. H.,Peng,A.,Villicana,R.,andJordan, S. C. (2008). Rituximab and intravenousimmuneglobulinfordesensitizationduringrenaltransplantation. N.Engl.J.Med.359,242-251.
170. Vugmeyster, Y., Seshasayee, D., Chang, W., Storn, A., Howell, K., Sa, S., Nelson, T., Martin, F., Grewal, I., Gilkerson, E., Wu, B., Thompson, J., Ehrenfels, B. N., Ren, S., Song, A., Gelzleichter, T. R., and Danilenko, D. M. (2006). A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginalzoneandfollicularBcellsin cynomolgus monkeys. Am. J. Pathol. 168, 476-489.
171. Waiser, J., Budde, K., Schutz, M., Liefeldt, L., Rudolph, B., Schonemann, C., Neumayer, H. H., and Lachmann, N. (2012). Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol. Dial. Transplant. 27,1246-1251.
172. Walker, L. S., Chodos, A., Eggena, M., Dooms, H., and Abbas, A. K. (2003). Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. 198,249-258.
173. Warnecke, G., Hutchinson, J. A., Riquelme, P., Kruse, B., Thissen, S., Avsar, M., Zehle, G., Steinkamp, T., Peters, C., Baumann, R., Govert, F., Ungefroren, H., Langer, F., Simon, A. R., Karstens, J. H., Kaever, V., Haverich, A., Fandrich, F., and Struber, M. (2009). Postoperative intra- venous infusion of donor-derived transplant acceptance-inducing cells as an adjunct immunosuppressive therapy in a porcine pulmonary allograft model. Transpl. Int. 22, 332-341.
174. Womer, K. L., and Kaplan, B. (2009). Recent developments in kidney transplantation-acritical assessment. Am. J. Transplant. 9, 1265- 1271.
175. Wood, K. J., and Sakaguchi, S. (2003). Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3, 199-210.
176. Xia, G., He, J., Zhang, Z., and Leventhal, J. R. (2006). Targeting acute allograft rejection by immunotherapy with ex vivoexpanded natural CD4+ CD25+ regulatoryTcells.Transplantation82, 1749-1755.
177. Xu, H., He, X., Liu, Q., Shi, D., Chen, Y., Zhu, Y., and Zhang, X. (2009a). Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant. Proc. 41,1552-1556.
178. Xu, H., He, X., Sun, J., Shi, D., Zhu, Y., and Zhang, X. (2009b). The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant. Proc. 41, 112-116.
179. Xu, H., Montgomery, S. P., Preston, E. H., Tadaki, D. K., Hale, D. A., Harlan, D. M., and Kirk, A. D. (2003). Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J. Immunol. 170,2776-2782.
180. Xu, H., Tadaki, D. K., Elster, E. A., Burkly, L. C., Berning, J. D., Cruzata, F., Kampen, R. L., Montgomery, S. P., Patterson, N. B., Harlan, D. M., and Kirk, A. D. (2002). Humani-zedanti-CD154antibodytherapyfor the treatment of allograft rejection in nonhuman primates. Transplantation 74, 940-943.
181. Yamazaki, S., Iyoda, T., Tarbell, K., Olson, K., Velinzon, K., Inaba, K., and Steinman, R. M. (2003). Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen- processing dendritic cells. J. Exp. Med. 198,235-247.
182. Yamazaki, S., Patel, M., Harper, A., Bonito, A., Fukuyama, H., Pack, M., Tarbell, K. V., Talmor, M., Ravetch, J. V., Inaba, K., and Steinman, R. M. (2006). Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction.Proc.Natl.Acad.Sci.U.S.A.103, 2758-2763.
183. Zarkhin, V., Li, L., and Sarwal, M. M. (2009). BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 88, 1229-1230.
184. Zeng,M.,Guinet,E.,andNouri-Shirazi, M. (2009). Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation. Transpl. Immunol. 22, 82-92.